(1R,3S)-3-ethylcyclohexan-1-ol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1R,3S)-3-ethylcyclohexan-1-ol
• 化学式: C₈H₁₆O
• 分子量: 128.214
• InChiKey: UNIOXDKEUNVBAC-JGVFFNPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-ethylcyclohexanone 在 sodium tetrahydroborate 、 1,4-dihydronicotinamide adenine dinucleotide 、 horse liver alcohol dehydrogenase 作用下， 生成 (+/-)-cis-3-ethyl-cyclohexanol 、 (+/-)-trans-3-ethyl-cyclohexanol 、 (1S,3S)-trans-3-ethylcyclohexanol 、 (1R,3S)-3-ethylcyclohexan-1-ol
  参考文献：
  名称：

  Use of shift reagent with MTPA derivatives in19F NMR spectrocopy: IV—Determination of enantiomeric composition for a variety of secondary cycloalkanols. A survey

  摘要：

  AbstractChiral secondary cycloalkanols (monocyclic alcohols) are derivatized to the corresponding (R)‐α‐methoxy‐α‐trifluoromethyl‐α‐phenylacetic acid [(R)‐MTPA] esters and analysed by 19F NMR in the presence of tris(6,6,7,7,8,8,8‐heptafluoro‐2,2‐dimethyl‐3,5‐octanedionato) europium(III) [Eu(fod)3]. Using this method the enantiomeric composition can be measured for several cyclopentanols, cyclohexanols and cycloheptanols, with a variety of substitution patterns. It is shown that a mixture of four stereoisomeric cycloalkanols, such as cis and trans disubstituted alcohols, can be analysed simultaneously.

  DOI：

  10.1002/omr.1270210609

文献信息

• TYK2 INHIBITORS AND USES THEREOF
  申请人：Nimbus Lakshmi, Inc.

  公开号：US20200131201A1

  公开（公告）日：2020-04-30

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了化合物、其组合物以及使用它们来抑制TYK2并治疗TYK2介导的疾病的方法。
• NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
  申请人：Merck Patent GmbH

  公开号：US20160168090A1

  公开（公告）日：2016-06-16

  The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及吲哚化合物及其药用可接受的组合物，用作P2X7拮抗剂，用于治疗与P2X7相关的疾病。
• [EN] NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS DE BENZIMIDAZOLE ET LEURS DÉRIVÉS EN TANT QU'INHIBITEURS D'EGFR
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2019162323A1

  公开（公告）日：2019-08-29

  The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

  本发明涵盖了式（I）（I）的化合物，其中基团R1至R5具有权利要求和说明书中给出的含义，它们作为突变EGFR的抑制剂的用途，含有这种化合物的药物组合物以及它们作为药物/医用品的用途，特别是作为治疗和/或预防肿瘤疾病的药剂。
• [EN] INDOLE AND AZAINDOLES DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS INDOLIQUES ET AZAINDOLIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：MERCK PATENT GMBH

  公开号：WO2016100281A1

  公开（公告）日：2016-06-23

  The present invention relates to indole and azaindole compounds of formula (I), and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.